• General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis

Article

GlobalMed Technologies acquires Omnilux Medical

Author(s):

GlobalMed has represented medical and aesthetic dermatology brands, including BMT, CoolTouch and Radiancy, since 1996. Omnilux noninvasively treats dermatologic conditions, including acne, fine lines and wrinkles and non-melanoma skin cancer.

Glen Ellen, Calif.-based GlobalMed Technologies has acquired Omnilux Medical, which trademarked a new skincare technology based on narrowband light emitting diodes (LEDs). The asset acquisition includes three Omnilux medical systems: Omnilux Revive2, Omnilux Blue and Omnilux Plus, along with many patents and trademarks, according to a May 16 press release.

As part of the deal, GlobalMed Technologies will get access to an installed base of more than 3,000 Omnilux systems worldwide. GlobalMed Technologies, a sales and marketing company for medical device manufacturers, has sold Omnilux outside the US since 2008, according to the company’s President Sanders Ergas.

GlobalMed has represented medical and aesthetic dermatology brands, including BMT, CoolTouch and Radiancy, since 1996. The company does business in more than 60 countries throughout Europe, the Middle East, Asia Pacific and the Americas.

Omnilux noninvasively treats dermatologic conditions, including acne, fine lines and wrinkles and non-melanoma skin cancer. There are more than 30 peer-reviewed clinical studies published in the literature looking at Omnilux’s safety and efficacy, according to the release.

Ergas says GlobalMed Technologies is considering the development of several new Omnilux applications.

“We view this transaction as a growth opportunity not only for the Company but for all our clients and stakeholders,” he says. 

Related Videos
Video 2 - 1 KOL featured in, "Adolescent Acne Management: Strategic Approaches and Leveraging Clascoterone Cream "
Video 1 - 1 KOL featured in, "Comprehensive Acne Management: Exploring the Role of Combination and Food Independent Treatments in an Adolescent Treatment-Naïve Patient "
Heather Woolery-Lloyd, MD, FAAD, an expert on acne
Heather Woolery-Lloyd, MD, FAAD, an expert on acne
Heather Woolery-Lloyd, MD, FAAD, an expert on acne
Heather Woolery-Lloyd, MD, FAAD, an expert on acne
© 2024 MJH Life Sciences

All rights reserved.